Latest news with #NeurentMedical
Yahoo
30-06-2025
- Health
- Yahoo
Neurent Medical Announces Expanded Access Following Cigna Policy Update for NEUROMARK®
Effective September 15, CPT 31242 is no longer considered experimental, clearing an important barrier for ENT physicians treating chronic rhinitis. GALWAY, Ireland, June 30, 2025 /PRNewswire/ -- Neurent Medical, a leader in non-surgical treatments for chronic rhinitis, today announced that Cigna Healthcare will provide coverage for NEUROMARK treatment of the posterior nasal nerve by removing CPT 31242 posterior nasal nerve ablation using radiofrequency from its Experimental & Investigational (E&I) list, effective September 15th, 2025. This policy update is an important step in improving patient access to innovative treatment options for chronic rhinitis and reflects growing payer recognition of the procedure's therapeutic value. This update removes a key barrier that previously limited the ability for ENT physicians to treat Cigna patients using posterior nasal nerve ablation. "This is a significant moment for ENT providers and patients alike," said Brian Shields, CEO of Neurent Medical. "Cigna's reclassification of CPT 31242 reinforces the evolving understanding of chronic rhinitis and the role of targeted, minimally invasive interventions like NEUROMARK in managing the condition. We are committed to continue building on our large evidence base and working closely with the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) to support adoption across the US healthcare system" The NEUROMARK System delivers impedance-controlled, low-power radiofrequency (RF) energy to disrupt the parasympathetic nerve signals, addressing key symptoms of Chronic Rhinitis such as persistent nasal congestion and rhinorrhea (runny nose). "Chronic rhinitis can significantly affect an individual's wellbeing and patients need access to all available, medically sound solutions" said Dr. Peter Manes, Associate Professor at Yale School of Medicine. "This policy update is significant and helps otolaryngologists offer a modern, evidence-supported treatment with fewer administrative hurdles. The large and growing evidence base makes it more difficult for patients to be denied access to such technologies." Key Points for Providers: CPT 31242 is no longer classified as investigational by Cigna Precertification is not required under the updated policy (always confirm benefits per individual plan) The policy supports more streamlined access to NEUROMARK for eligible patients To view Cigna's updated medical policy, visit:CIGNA Policy LINK For more information about NEUROMARK, visit or contact your local Neurent Medical Sales Representative. About Neurent Medical Neurent Medical is pioneering innovative treatments for chronic inflammatory sinonasal diseases by targeting and safely disrupting hyperactive autonomic nerves that drive underlying inflammation. Its proprietary NEUROMARK® technology, with a unique design and advanced smart algorithmic control, allows physicians to precisely target and safely disrupt multiple underlying nerve branches in a single procedure to alleviate chronic rhinitis symptoms and improve patient quality of life. The venture capital-backed company is headquartered in Galway, Ireland, with US HQ in Braintree, MA. For more information visit PAM225r01 View original content to download multimedia: SOURCE Neurent Medical
Irish Post
17-06-2025
- Business
- Irish Post
Minister attends opening of leading Irish medtech firm's new manufacturing facility
A LEADING Irish medtech firm has opened a new state-of-the-art manufacturing facility in Co. Galway to increase production on one of its leading products. Neurent Medical has produced a non-surgical solution for people suffering with chronic rhinitis - a persistent inflammation of the nasal passages, which can cause symptoms such as a runny nose, nasal congestion, and post-nasal drip for more than 12 weeks. Their product Neuromark targets the underlying drivers of the condition so effectively that there is growing demand for the technology both in Ireland and in the US. To meet demand, the firm has launched its new manufacturing site at Westlink Commercial Park in Oranmore. Pictured (l-r) Minister Hildegarde Naughton, Jenny Melia of Enterprise Ireland and Brian Shields, CEO Neurent Medical 'We're proud to scale our operations in Galway, where the MedTech ecosystem continues to thrive,' Neurent Medical CEO Brian Shields said. 'Our new Westlink facility gives us the manufacturing capacity to meet growing demand for Neuromark, while creating high skilled employment opportunities and contributing to economic vitality in the west of Ireland.' He added: 'As an Irish-founded company, we're excited to manufacture our product locally with the exceptional skills available and deliver Irish-engineered MedTech innovation to the world.' The new facility will bring 125 new highly skilled jobs to the Galway area by the end of 2028, the company has confirmed. The new jobs will range across key functions in engineering, quality control, operations, supply chain management, and sales and marketing. Originating from the Enterprise Ireland-supported BioInnovate Ireland Programme, Neurent Medical has grown from concept to commercialisation within a decade, emerging as one of Ireland's medtech success stories. Minister Hildegarde Naughton and Jenny Melia, CEO (Designate) of Enterprise Ireland, who have supported the firm, were at the opening of the new site. 'I want to congratulate Neurent Medical on this significant achievement,' Minister Naighton said. 'Galway is known as a major player in medical technology, being home to eight of the world's top 10 medtech companies. 'As a native myself, I am particularly proud to see 125 new highly skilled jobs being created by a company based in Oranmore,' she added. 'It is also highly notable that this is an Irish company, supported by Enterprise Ireland, and selling into the US market. 'I have no doubt, given their impressive growth to date, that this will be but one of many major achievements for the company.' See More: Enterprise Ireland, Galway, Irish, Medtech, Neurent Medical
Irish Independent
17-06-2025
- Business
- Irish Independent
Over 100 jobs set for Galway as leading medical company opens new facility
Located in Westlink Commercial Park, the opening of the new state-of-the-art manufacturing facility marks a 'significant' milestone for the company. The new facility will create 125 new highly skilled jobs by the end of 2028 and will serve as the central hub to produce the company's Neuromark system. The Neuromark system is a minimally invasive medical device designed to target the underlying drivers of chronic rhinitis. The new jobs will range across key functions in engineering, quality control, operations, supply chain management, and sales and marketing. Originating from the Enterprise Ireland-supported BioInnovate Ireland Programme, Neurent Medical has grown from concept to commercialisation within a decade, emerging as one of Ireland's MedTech success stories. The official opening event was celebrated with Galway West TD Hildegarde Naughton TD and executive director and incoming CEO of Enterprise Ireland Jenny Melia. Brian Shields, CEO of Neurent Medical, said the company is proud to upgrade its operations in Galway, where the company is headquartered. 'Our new Westlink facility gives us the manufacturing capacity to meet growing demand for NEUROMARK, while creating high skilled employment opportunities and contributing to economic vitality in the west of Ireland,' he said. 'As an Irish-founded company, we're excited to manufacture our product locally with the exceptional skills available and deliver Irish-engineered MedTech innovation to the world.' Ms Melia said the announcement of new jobs for the new Oranmore base shows that Ireland is a research and development leader within the medical device space. "Supporting Irish companies with the ambition to scale globally is a key priority for Enterprise Ireland and we will continue to work closely with Brian and the team at Neurent Medical to optimise their full international growth potential, creating and sustaining jobs here in the Galway region," she added. Deputy Naughton noted that Galway is home to eight of the world's top 10 MedTech companies. "It is also highly notable that this is an Irish company, supported by Enterprise Ireland, and selling into the US market. I have no doubt, given their impressive growth to date, that this will be but one of many major achievements for the company," she added.
Irish Examiner
17-06-2025
- Business
- Irish Examiner
Medtech firm Neurent to create 125 jobs in Galway hub
Healthcare company Neurent Medical is to create 125 jobs in Galway at its new manufacturing facility at Westlink Commercial Park in Oranmore. The company is a leader in ear, nose, and throat (ENT) healthcare solutions and will create positions in engineering, quality control, operations, supply chain, and sales and marketing at the new facility, over the next three years. The Galway headquarters will serve as a hub for production of the company's Neuromark treatment option to treat chronic rhinitis. 'We're proud to scale our operations in Galway, where the medtech ecosystem continues to thrive. Our new Westlink facility gives us the manufacturing capacity to meet growing demand for Neuromark, while creating high skilled employment opportunities and contributing to economic vitality in the west of Ireland," said Neurent Medical chief Brian Shields. Neurent's Neuromark system recently received US FDA 510(k) clearance, which paves the way for broader commercialisation of its product in the US. "Neurent Medical has experienced impressive growth in a short period of time beginning its journey through the BioInnovate Ireland Programme here in Galway with further support awarded through EI's Commercialisation fund programme and through the Disruptive Technologies Innovation Fund administered by Enterprise Ireland for the development of the NEUROMARK technology,' said incoming Enterprise Ireland chief Jenny Melia.
RTÉ News
17-06-2025
- Business
- RTÉ News
Neurent Medical to create 125 jobs in Galway
Healthcare company Neurent Medical is to create 125 new highly skilled jobs in Galway over the next three years. The announcement comes as the company officially opened its new state-of-the-art manufacturing facility at Westlink Commercial Park in Oranmore. The new facility will serve as the central hub for the production of the company's Neuromark system, a treatment option designed to target the underlying drivers of chronic Rhinitis. The new Galway jobs will range across key functions in engineering, quality control, operations, supply chain management, and sales and marketing. Originating from the Enterprise Ireland-supported BioInnovate Ireland Programme, Neurent Medical has grown from concept to commercialisation within a decade, emerging as one of the country's MedTech success stories. Since its inception, it said it has leveraged Galway's world-class innovation ecosystem to scale its team, secure FDA regulatory clearances and attract top international clinical collaborators. Brian Shields, CEO of Neurent Medical, said the company was proud to scale its operations in Galway, where the MedTech ecosystem continues to thrive. "Our new Westlink facility gives us the manufacturing capacity to meet growing demand for Neuromark, while creating high skilled employment opportunities and contributing to economic vitality in the west of Ireland," he said. "As an Irish-founded company, we're excited to manufacture our product locally with the exceptional skills available and deliver Irish-engineered MedTech innovation to the world," he added. Jenny Melia, Executive Director and incoming CEO at Enterprise Ireland, said today's announcement of new jobs based here in Oranmore shows that Ireland is leading in research and development within the medical device space. "Neurent Medical has experienced impressive growth in a short period of time beginning its journey through the BioInnovate Ireland Programme here in Galway with further support awarded through EI's Commercialisation fund programme and through the Disruptive Technologies Innovation Fund administered by Enterprise Ireland for the development of the Neuromark technology," she said. "Supporting Irish companies with the ambition to scale globally is a key priority for Enterprise Ireland and we will continue to work closely with Brian and the team at Neurent Medical to optimise their full international growth potential, creating and sustaining jobs here in the Galway region," she added. Hildegarde Naughton, Minister of State at the Department of Children, Disability and Equality, noted that Galway is home to eight of the world's top 10 MedTech companies. "It is also highly notable that this is an Irish company, supported by Enterprise Ireland, and selling into the US market. I have no doubt, given their impressive growth to date, that this will be but one of many major achievements for the company," she added.
